10 348
2014 Annual Report
Prysmian Group
10
2014
2013 (**)
Change %
2012 (**)
Sales
6,840
6,995
-2.2%
7,574
Adjusted EBITDA before share of net profit/(loss)
of equity-accounted companies
466
578
-19.5%
619
Adjusted EBITDA
(2)
509
613
-17.0%
650
EBITDA
(1)
496
563
-12.2%
549
Adjusted operating income
(3)
365
465
-21.5%
494
Operating income
312
368
-15.6%
373
Profit/(loss) before taxes
172
218
-21.3%
239
Net profit/(loss) for the year
115
153
-24.7%
167
31 December 2014 31 December 2013 (**)
Change
31 December 2012 (**)
Net capital employed
2,345
2,296
49
2,379
Employee benefit obligations
360
308
52
344
Equity
1,183
1,183
-
1,147
of which attributable to non-controlling interests
33
36
(3)
35
Net financial position
802
805
(3)
888
2014
2013 (**)
Change %
2012 (**)
Capital expenditure
(4)
163
136
19.9%
139
Employees (at period end)
19,436
19,232
1.1%
19,769
Earnings/(loss) per share
- basic
0.54
0.71
0.79
- diluted
0.54
0.71
0.78
Patents (***)
5,836
5,731
5,644
Number of plants
89
91
91
Percentage of plants certified ISO 14001
93%
86%
82%
Percentage of plants certified OHSAS 18001
59%
49%
42%
(1) EBITDA is defined as earnings/(loss) for the year, before the fair value change in metal derivatives and in other fair value items, amortisation, depreciation,
and impairment, finance costs and income and dividends from other companies and taxes.
(2) Adjusted EBITDA is defined as EBITDA before non-recurring income/(expenses).
(3) Adjusted operating income is defined as operating income before non-recurring income/(expenses) and the fair value change in metal derivatives and in
other fair value items.
(4) Capital expenditure refers to increases in Property, plant and equipment and Intangible assets, gross of leased assets.
(*) All percentages contained in this report have been calculated with reference to amounts expressed in thousands of Euro.
(**) The previously published prior year comparative figures have been restated following the introduction of IFRS 10 and IFRS 11 and a new method of classifying
the share of net profit (loss) of associates and joint ventures.
(***)These are the total number of patents, comprising patents granted plus patent applications pending worldwide.
MAIN FINANCIAL AND OPERATING DATA
(*)
(in millions of Euro)
(in millions of Euro)
(in millions of Euro)
Consolidated Financial Report |
DIRECTORS’ REPORT
FINANCIAL HIGHLIGHTS